Search results
Results from the WOW.Com Content Network
A phosphate concentration greater than 1.46 mmol/L (4.5 mg/dL) is indicative of hyperphosphatemia, though further tests may be needed to identify the underlying cause of the elevated phosphate levels. [5] It is considered significant when levels are greater than 1.6 mmol/L (5 mg/dL). [2]
Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. [1] [4] This occurs from a disorder either within the parathyroid glands (primary hyperparathyroidism) or as response to external stimuli (secondary hyperparathyroidism). [1]
Symptoms of hypernatremia may vary depending on type and how quickly the electrolyte disturbance developed. [27] Common symptoms are dehydration, nausea, vomiting, fatigue, weakness, increased thirst, and excess urination. Patients may be on medications that caused the imbalance such as diuretics or nonsteroidal anti-inflammatory drugs. [27]
Tertiary hyperparathyroidism is a condition involving the overproduction of the hormone, parathyroid hormone, produced by the parathyroid glands. [1] The parathyroid glands are involved in monitoring and regulating blood calcium levels and respond by either producing or ceasing to produce parathyroid hormone.
There may be symptoms of thyroid overactivity, such as weight loss, a fast or irregular heart rate, tremor, and perspiration; [1] [2] but such symptoms occur in only half of all cases. [5] The most common type of hyperthyroidism, Graves' disease , may additionally cause eye problems ( Graves' ophthalmopathy ) and skin changes of the legs ...
Statins (prescription drugs to lower cholesterol) are considered a small risk. [9] Some people have inherited muscle conditions that increase the risk of rhabdomyolysis. [3] The diagnosis is supported by a urine test strip which is positive for "blood" but the urine contains no red blood cells when examined with a microscope. [3]
The drugs are called proton pump inhibitors, or PPIs, and you might even have one or two in your medicine cabinet right now. Using some heartburn drugs may increase your risk of kidney problems ...
Treatment of postmenopausal women with 2.5 or 5 mg/day MPA in combination with estradiol valerate for two weeks has been found to rapidly increase circulating MPA levels, with steady-state concentrations achieved after three days and peak concentrations occurring 1.5 to 2 hours after ingestion.